RGS 0.00% 12.0¢ regeneus ltd

CEO talks about regenerative medecine, page-6

  1. 314 Posts.
    lightbulb Created with Sketch. 4
    Like any micro cap,and especially medically oriented ones,the R&D cost are such a big part of the business that investors may be concerned there will be regular capital raisings. There is also a very long lead time from trials to regulatory approvals that again the chance of capital raising is high,along with possible failure of the medical trial. I have faith in RGS and if all my comments above were non existent the stock would be ten to fifteen times the current sp.I am happy as a shareholder to provide further capital if needed.
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.